<div id="readability-page-1"><div><p>As Asian markets experience fluctuations amid global economic shifts, investors are increasingly focused on identifying opportunities within the region's diverse landscape. In this environment, stocks that appear undervalued present intriguing possibilities for those looking to capitalize on potential market inefficiencies.</p><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Current Price</strong></td><td><strong>Fair Value (Est)</strong></td><td><strong>Discount (Est)</strong></td></tr><tr><td>SRE Holdings (TSE:2980)</td><td>¥3180.00</td><td>¥6197.35</td><td>48.7%</td></tr><tr><td>SILICON2 (KOSDAQ:A257720)</td><td>₩53700.00</td><td>₩105825.30</td><td>49.3%</td></tr><tr><td>Nanya Technology (TWSE:2408)</td><td>NT$43.95</td><td>NT$87.09</td><td>49.5%</td></tr><tr><td>Jiangsu Yunyi ElectricLtd (SZSE:300304)</td><td>CN¥11.08</td><td>CN¥22.02</td><td>49.7%</td></tr><tr><td>Heartland Group Holdings (NZSE:HGH)</td><td>NZ$0.80</td><td>NZ$1.58</td><td>49.5%</td></tr><tr><td>Guangdong Marubi Biotechnology (SHSE:603983)</td><td>CN¥40.73</td><td>CN¥79.37</td><td>48.7%</td></tr><tr><td>GEM (SZSE:002340)</td><td>CN¥6.54</td><td>CN¥13.00</td><td>49.7%</td></tr><tr><td>Finger (KOSDAQ:A163730)</td><td>₩13480.00</td><td>₩26287.84</td><td>48.7%</td></tr><tr><td>cottaLTD (TSE:3359)</td><td>¥442.00</td><td>¥868.15</td><td>49.1%</td></tr><tr><td>Andes Technology (TWSE:6533)</td><td>NT$276.50</td><td>NT$541.44</td><td>48.9%</td></tr></tbody></table><p>Click here to see the full list of 282 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p><p>We'll examine a selection from our screener results.</p><h2>Cofco Sugar HoldingLTD (SHSE:600737)</h2><p><strong>Overview:</strong> Cofco Sugar Holding Co., Ltd. operates in sugar and tomato processing both in China and internationally, with a market cap of CN¥21.84 billion.</p><p><strong>Operations:</strong> Cofco Sugar Holding CO., LTD. generates revenue primarily through its activities in sugar and tomato processing across domestic and international markets.</p><p><strong>Estimated Discount To Fair Value:</strong> 40.3%</p><p>Cofco Sugar Holding LTD is trading at CN¥10.21, significantly below its estimated fair value of CN¥17.11, indicating potential undervaluation based on discounted cash flow analysis. The company's earnings are forecast to grow significantly at 36.89% annually, outpacing the Chinese market's average growth rate of 23.6%. While revenue growth is expected to be robust at 18% per year, investors should note the unstable dividend track record when considering long-term cash flow sustainability.</p><ul><li>The growth report we've compiled suggests that Cofco Sugar HoldingLTD's future prospects could be on the up.</li><li>Dive into the specifics of Cofco Sugar HoldingLTD here with our thorough financial health report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>SHSE:600737 Discounted Cash Flow as at Aug 2025</figcaption></figure><h2>Guangdong Marubi Biotechnology (SHSE:603983)</h2><p><strong>Overview:</strong> Guangdong Marubi Biotechnology Co., Ltd. focuses on the research, design, production, sale, and service of cosmetics in China with a market cap of CN¥16.33 billion.</p><p><strong>Operations:</strong> The company's revenue primarily comes from its Personal Products segment, which generated CN¥3.16 billion.</p><p><strong>Estimated Discount To Fair Value:</strong> 48.7%</p><p>Guangdong Marubi Biotechnology is trading at CN¥40.73, significantly below its estimated fair value of CN¥79.37, highlighting potential undervaluation based on discounted cash flow analysis. The company's earnings are forecast to grow at 23.7% annually, slightly outpacing the Chinese market's average growth rate. Revenue is expected to increase by 21.5% per year, surpassing market expectations; however, the dividend yield of 1.84% lacks coverage from free cash flows and return on equity remains modest at 15.2%.</p><ul><li>The analysis detailed in our Guangdong Marubi Biotechnology growth report hints at robust future financial performance.</li><li>Delve into the full analysis health report here for a deeper understanding of Guangdong Marubi Biotechnology.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>SHSE:603983 Discounted Cash Flow as at Aug 2025</figcaption></figure><h2>MeHow Innovative (SZSE:301363)</h2><p><strong>Overview:</strong> MeHow Innovative Ltd. is a company that designs, develops, manufactures, and sells precision medical device components and products in China and internationally, with a market cap of CN¥11.33 billion.</p><p><strong>Operations:</strong> Revenue Segments (in millions of CN¥):</p><p><strong>Estimated Discount To Fair Value:</strong> 32.6%</p><p>MeHow Innovative is trading at CN¥20.03, below its estimated fair value of CN¥29.72, suggesting undervaluation based on discounted cash flow analysis. Earnings are projected to grow 22.87% annually over the next three years, although slightly lagging behind the broader Chinese market growth rate of 23.6%. Revenue growth is expected to be robust at 21.4% per year, outpacing the market average of 12.6%, despite a forecasted return on equity of only 13.1%.</p><ul><li>Upon reviewing our latest growth report, MeHow Innovative's projected financial performance appears quite optimistic.</li><li>Click to explore a detailed breakdown of our findings in MeHow Innovative's balance sheet health report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>SZSE:301363 Discounted Cash Flow as at Aug 2025</figcaption></figure><h2>Taking Advantage</h2><ul><li>Access the full spectrum of 282 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.</li><li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li><li>Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.</li></ul><h2>Searching for a Fresh Perspective?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.      It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

600737

603983

<p>As Asian markets fluctuate, investors are identifying undervalued stocks. Notable mentions include SRE Holdings, SILICON2, and Nanya Technology, with estimated discounts of 48.7% to 49.5%. Cofco Sugar Holding and Guangdong Marubi Biotechnology also show significant undervaluation, with discounts of 40.3% and 48.7%, respectively. Both companies are expected to experience robust earnings growth, although concerns about dividend sustainability exist. The analysis suggests potential investment opportunities in these undervalued stocks based on cash flow assessments.</p>

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 48.7%